BlueRock Therapeutics
Clinical stage company to transform the treatment of disease by harnessing the power of cell therapy
BlueRock Therapeutics is a clinical stage cell therapy company focused on creating cellular medicines to reverse devastating diseases. BlueRock was founded in 2016 as a joint venture of Versant Ventures and Leaps by Bayer. In late 2019, it became a wholly owned, independently operated subsidiary of Bayer AG as a cornerstone of its newly formed Cell & Gene Therapy Platform.
The company's cell & gene therapy platform harnesses the power of cells to create new medicines for neurology, cardiology, and immunology indications. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function.
Visit website: https://www.bluerocktx.com/
Details last updated 13-Jul-2023
People at BlueRock Therapeutics
BlueRock Therapeutics News
Bluerock to pioneer first-in-class neuronal stem cell therapy for Parkinson’s disease
BlueRock Therapeutics - 28-Jun-2023
Bemdaneprocel shows positive phase I results, advances to Phase II trial in early 2024
Read more...